Lenalidomide plus rituximab elicits favorable response in follicular lymphoma

July 25, 2017

The combination of lenalidomide and rituximab followed by maintenance resulted in favorable activity and tolerability in patients with follicular lymphoma considered double refractory or early relapsers, according to a phase 3b randomized study presented at the ASCO Annual Meeting. Featuring Andre Goy, MD, MS.

Read full article on healio.com